Eli Lilly Price to Sales Ratio 2010-2023 | LLY

Historical PS ratio values for Eli Lilly (LLY) over the last 10 years. The current P/S ratio for Eli Lilly as of April 19, 2024 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Eli Lilly P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2024-04-19 726.31 19.20
2023-12-31 581.92 $37.82 15.38
2023-09-30 535.22 $35.54 15.06
2023-06-30 466.33 $32.67 14.28
2023-03-31 340.60 $30.64 11.11
2022-12-31 361.66 $31.55 11.46
2022-09-30 318.77 $32.26 9.88
2022-06-30 318.63 $32.01 9.95
2022-03-31 280.48 $32.23 8.70
2021-12-31 269.41 $31.07 8.67
2021-09-30 224.62 $30.45 7.38
2021-06-30 222.42 $29.31 7.59
2021-03-31 180.25 $27.95 6.45
2020-12-31 162.22 $26.92 6.03
2020-09-30 141.48 $25.30 5.59
2020-06-30 156.15 $24.96 6.26
2020-03-31 131.33 $25.02 5.25
2019-12-31 123.78 $23.77 5.21
2019-09-30 104.71 $22.69 4.62
2019-06-30 103.74 $21.90 4.74
2019-03-31 120.83 $21.22 5.69
2018-12-31 107.19 $20.77 5.16
2018-09-30 98.89 $18.42 5.37
2018-06-30 78.21 $18.61 4.20
2018-03-31 70.42 $18.70 3.77
2017-12-31 76.32 $18.92 4.03
2017-09-30 76.81 $21.24 3.62
2017-06-30 73.43 $20.78 3.53
2017-03-31 74.56 $20.37 3.66
2016-12-31 64.77 $19.99 3.24
2016-09-30 70.22 $19.61 3.58
2016-06-30 68.46 $19.37 3.53
2016-03-31 62.19 $18.95 3.28
2015-12-31 72.26 $18.73 3.86
2015-09-30 71.33 $18.45 3.87
2015-06-30 70.74 $18.33 3.86
2015-03-31 61.13 $18.24 3.35
2014-12-31 57.64 $18.24 3.16
2014-09-30 53.79 $18.83 2.86
2014-06-30 51.15 $19.62 2.61
2014-03-31 48.04 $20.50 2.34
2013-12-31 41.24 $21.28 1.94
2013-09-30 40.31 $21.26 1.90
2013-06-30 39.00 $20.79 1.88
2013-03-31 44.69 $20.33 2.20
2012-12-31 38.46 $20.25 1.90
2012-09-30 36.59 $20.34 1.80
2012-06-30 32.74 $21.00 1.56
2012-03-31 30.36 $21.61 1.41
2011-12-31 30.95 $21.81 1.42
2011-09-30 27.17 $21.98 1.24
2011-06-30 27.21 $21.58 1.26
2011-03-31 25.18 $21.17 1.19
2010-12-31 24.73 $20.89 1.18
2010-09-30 25.43 $20.70 1.23
2010-06-30 23.01 $20.65 1.11
2010-03-31 24.53 $20.27 1.21
2009-12-31 23.85 $19.89 1.20
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $690.114B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $550.665B 45.36
Johnson & Johnson (JNJ) United States $356.431B 14.14
Merck (MRK) United States $318.604B 83.85
AbbVie (ABBV) United States $294.653B 14.98
AstraZeneca (AZN) United Kingdom $212.533B 18.83
Novartis AG (NVS) Switzerland $200.005B 13.86
Pfizer (PFE) United States $147.226B 14.21
Sanofi (SNY) $117.121B 10.55
Innoviva (INVA) United States $0.945B 6.67